"C" is for costs, and cancer, and conference: Highlights of the first european conference on the economics of cancer

Journal of Oncology Pharmacy Practice

Volumn 4, Issue 3, 1998, Pages 125-128

  Taylor, Suzanne C ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71949103567     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529800400205     Document Type: Article

References (13)

1. The first European conference on the economics of cancer. Eur J Cancer. 1997;33(Suppl. 9).
2. Gelber RD, Cole BF, Gelber s,et al.The Q-TWiST method. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd Ed. New York: Raven Press; 1995:427- 435.
3. Goldhirsch A., Gelber RD, Simes RJ,et al.Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989;7:36-44.
4. Cole BF, Gelber RD, Kirkwood JM,et al.Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666-2673.
5. Brown ML, Nayfield SG, Shibley LM Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst. 1994;86:424 - 430.
6. American Society of Clinical Oncology Outcomes Working Group. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996; 14:671- 679.
7. Smith TJ, Hillner BE, Schmitz N.,et al.Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:5-10.
8. Goodwin PJ, Feld R., Evans WK,et al.Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988;6:1537-1547.
9. Jaakkimaimen L., Goodwin PJ, Pater J.,et al.Counting the costs of cancer chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol. 1990;8:1301-1309.
10. Evans WK, Will BP, Berthelot J-M.,et al.The economics of lung cancer management in Canada. Lung Cancer. 1996;14:19-29.
11. Smith TJ, Hillner BE, Neighbors DM,et al.Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol. 1995;13:2166 -2173.
12. Desch CE, Hillner BE, Smith TJ Economic considerations in the care of lung cancer patients. Curr Opin Oncol. 1996;8:126-132.
13. Barendregt JJ, Bonneux L., Van Der Maas PJ The health care costs of smoking. New Engl J Med. 1997;337:1052-1057.